Cargando…
Impaired HMG-CoA Reductase Activity Caused by Genetic Variants or Statin Exposure: Impact on Human Adipose Tissue, β-Cells and Metabolome
Inhibition of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase is associated with an increased risk of new-onset type 2 diabetes. We studied the association of genetic or pharmacological HMG-CoA reductase inhibition with plasma and adipose tissue (AT) metabolome and AT metabolic pathways. We also...
Autores principales: | Sarsenbayeva, Assel, Jui, Bipasha Nandi, Fanni, Giovanni, Barbosa, Pedro, Ahmed, Fozia, Kristófi, Robin, Cen, Jing, Chowdhury, Azazul, Skrtic, Stanko, Bergsten, Peter, Fall, Tove, Eriksson, Jan W., Pereira, Maria J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468287/ https://www.ncbi.nlm.nih.gov/pubmed/34564389 http://dx.doi.org/10.3390/metabo11090574 |
Ejemplares similares
-
Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase
por: Würtz, Peter, et al.
Publicado: (2016) -
Targeting Enterococcus faecalis HMG-CoA reductase with a non-statin inhibitor
por: Bose, Sucharita, et al.
Publicado: (2023) -
Predictive Modeling
of HMG-CoA Reductase Inhibitory
Activity and Design of New HMG-CoA Reductase Inhibitors
por: Samizo, Shigeyoshi, et al.
Publicado: (2023) -
HMG CoA reductase inhibitors (statins) to treat Epstein–Barr virus-driven lymphoma
por: Cohen, J I
Publicado: (2005) -
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
por: Palmer, Suetonia C., et al.
Publicado: (2015)